Literature DB >> 22030901

Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates.

Kui Li1, Nan L Li, Dahai Wei, Susan R Pfeffer, Meiyun Fan, Lawrence M Pfeffer.   

Abstract

UNLABELLED: Chemokines and inflammatory cytokines are key regulators of immunity and inflammation during viral infections. Hepatitis C virus (HCV) is a hepatotropic RNA virus frequently associated with chronic liver inflammation and hepatocellular carcinoma. Intrahepatic levels of chemokines and cytokines are elevated in chronic HCV infections, but the underlying mechanisms remain unclear. We found that Toll-like receptor-3 (TLR3) senses HCV infection in cultured hepatoma cells, leading to nuclear factor kappa B (NF-κB) activation and the production of numerous chemokines and inflammatory cytokines, such as regulated on activation normal T cell expressed and secreted (RANTES), macrophage inflammatory protein (MIP)-1α, MIP-1β, IP-10, and interleukin-6. The chemokine/cytokine induction occurred late in HCV infection and was abrogated when HCV was ultraviolet-inactivated before infection, indicating a dependence on the cellular recognition of HCV replication products. Gel-shift and chromatin immunoprecipitation assays revealed that NF-κB plays a pivotal role in HCV-induced chemokine/cytokine transcription. Mutations specifically disrupting the double-stranded RNA (dsRNA)-binding activity of TLR3 ablated the chemokine/cytokine response to HCV infection, indicating that HCV dsRNA was the pathogen-associated molecular pattern triggering TLR3 signaling. In vitro synthesized HCV dsRNAs, with a minimal length of ∼80-100 base pairs, activated TLR3-dependent chemokine expression, regardless of the genome position from which they derived. In contrast, HCV single-stranded RNAs, including those derived from the structured 3'nontranslated region highly potent for RIG-I activation, failed to do so. Moreover, robust production of chemokines and inflammatory cytokines was also observed in primary human hepatocytes after stimulation with extracellular poly-I:C, a TLR3 ligand.
CONCLUSION: Our data suggest that TLR3-mediated chemokine and inflammatory cytokine responses may play an important role in host immune responses to HCV and the pathogenesis of HCV-associated liver diseases.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22030901      PMCID: PMC3272326          DOI: 10.1002/hep.24763

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  26 in total

1.  Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF.

Authors:  Kui Li; Eileen Foy; Josephine C Ferreon; Mitsuyasu Nakamura; Allan C M Ferreon; Masanori Ikeda; Stuart C Ray; Michael Gale; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

2.  Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.

Authors:  Etienne Meylan; Joseph Curran; Kay Hofmann; Darius Moradpour; Marco Binder; Ralf Bartenschlager; Jürg Tschopp
Journal:  Nature       Date:  2005-09-21       Impact factor: 49.962

3.  Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes.

Authors:  Kui Li; Zihong Chen; Nobuyuki Kato; Michael Gale; Stanley M Lemon
Journal:  J Biol Chem       Date:  2005-02-28       Impact factor: 5.157

4.  Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro.

Authors:  Po-Yuan Ke; Steve S-L Chen
Journal:  J Clin Invest       Date:  2010-12-06       Impact factor: 14.808

5.  Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I.

Authors:  Rhea Sumpter; Yueh-Ming Loo; Eileen Foy; Kui Li; Mitsutoshi Yoneyama; Takashi Fujita; Stanley M Lemon; Michael Gale
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.

Authors:  L Alexopoulou; A C Holt; R Medzhitov; R A Flavell
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

Review 7.  Adaptive immune responses in acute and chronic hepatitis C virus infection.

Authors:  David G Bowen; Christopher M Walker
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

8.  Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B.

Authors:  K Natarajan; S Singh; T R Burke; D Grunberger; B B Aggarwal
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

9.  Toll IL-1 receptors differ in their ability to promote the stabilization of adenosine and uridine-rich elements containing mRNA.

Authors:  Shyamasree Datta; Michael Novotny; Xiaoxia Li; Julie Tebo; Thomas A Hamilton
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

10.  Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity.

Authors:  Xiao-Dong Li; Lijun Sun; Rashu B Seth; Gabriel Pineda; Zhijian J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-21       Impact factor: 11.205

View more
  91 in total

1.  Geographical, environmental and pathophysiological influences on the human blood transcriptome.

Authors:  Rubina Tabassum; Artika Nath; Marcela Preininger; Greg Gibson
Journal:  Curr Genet Med Rep       Date:  2013-12

Review 2.  Regulation of hepatic innate immunity by hepatitis C virus.

Authors:  Stacy M Horner; Michael Gale
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

Review 3.  Insights into antiviral innate immunity revealed by studying hepatitis C virus.

Authors:  Stacy M Horner
Journal:  Cytokine       Date:  2015-03-25       Impact factor: 3.861

4.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

5.  TRIM56 is an essential component of the TLR3 antiviral signaling pathway.

Authors:  Yang Shen; Nan L Li; Jie Wang; Baoming Liu; Sandra Lester; Kui Li
Journal:  J Biol Chem       Date:  2012-09-04       Impact factor: 5.157

Review 6.  Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer.

Authors:  Jessica Brownell; Stephen J Polyak
Journal:  Clin Cancer Res       Date:  2013-01-15       Impact factor: 12.531

Review 7.  Immune responses to HCV and other hepatitis viruses.

Authors:  Su-Hyung Park; Barbara Rehermann
Journal:  Immunity       Date:  2014-01-16       Impact factor: 31.745

Review 8.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

9.  Association of Toll-like receptor 3 polymorphisms with chronic hepatitis B and hepatitis B-related acute-on-chronic liver failure.

Authors:  Yihui Rong; Haihan Song; Shaoli You; Bing Zhu; Hong Zang; Yi Zhao; Yongli Li; Zhihong Wan; Hongling Liu; Aimin Zhang; Long Xiao; Shaojie Xin
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

Review 10.  Intrahepatic regulation of antiviral T cell responses at initial stages of viral infection.

Authors:  Yuejin Liang; Zakari Kwota; Jiaren Sun
Journal:  Int Immunopharmacol       Date:  2016-07-25       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.